Expression of IRF-4 and IBP in skin lesions of patients with psoriasis vulgaris

Abstract

The expression of the interferon regulatory factor 4 (IRF-4) and the IRF-4-binding protein (IBP) in psoriatic skin lesions was investigated. The expression of IRF-4 and IBP in skin lesions of 20 patients with psoriasis vulgaris were immunohistochemically dectected. Normal skin from 10 healthy people was used as normal control. The study showed that expression of IRF-4 was increased significantly in keratinocytes and inflammatory cells in the lesions of psoriasis vulgaris than that in the normal control. The detection revealed that IBP expression in keratinocytes, lymphocytes, hair follicles, and sebaceous glands in normal skin was significantly lower than that in the lesions of psoriasis vulgaris (P<0.05). Both IRF-4 and IBP might be involved in the pathogenesis of psoriasis vulgaris.

Keywords

psoriasis / IRF-4 / IBP

References

[1] BucknerJ.H.. Mechanisms of impaired regulation by CD4+CD25+FOXP3+ regulatory T cells in human autoimmune diseases. Nat Rev Immunol, 2010, 10(12): 849-859

[2] OuyangW., KollsJ.K., ZhengY., et al.. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity, 2008, 28(4): 454-467

[3] Di CesareA., Di MeglioP., NestleF.O., et al.. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol, 2009, 129(6): 1339-1350

[4] BrüstleA., HeinkS., HuberM., et al.. The development of inflammatory T(H)-17 cells requires interferon-regulatory factor 4. Nat Immunol, 2007, 8(9): 958-966

[5] GuptaS., LeeA., HuC., et al.. Molecular cloning of IBP, a SWAP-70 homologous GEF, which is highly expressed in the immune system. Hum Immunol, 2003, 64(4): 389-401

[6] ChenQ., YangW., GuptaS., et al.. IRF-4-binding protein inhibits interleukin-17 and interleukin-21 production by controlling the activity of irf-4 transcription factor. Immunity, 2008, 29(6): 899-911

[7] Canonigo-BalancioA.J., FosC., Prod’hommeT., et al.. SLAT/Def6 plays a critical role in the development of th17 cell-mediated experimental autoimmune encephalomyelitis. J Immunol, 2009, 183(11): 7259-7267

[8] LowesM.A., KikuchiT., Fuentes-DuculanJ., et al.. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol, 2008, 128(5): 1207-1211

[9] LiJ., ChenX., LiuZ., et al.. Expression of Th17 cytokines in skin lesions of patients with psoriasis. Huazhong Univ Sci Technolog [Med Sci], 2007, 27(3): 330-332

[10] HuberM., BrüstleA., ReinhardK., et al.. IRF4 is essential for IL-21-mediated induction, amplification, and stabilization of the Th17 phenotype. Proc Natl Acad Sci USA, 2008, 105(52): 20 846-20 851

[11] CarusoR., BottiE., SarraM., et al.. Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med, 2009, 15(9): 1013-1015

[12] ShafferA.L., EmreN.C., RomesserP.B., et al.. IRF4: Immunity. Malignancy! Therapy?. Clin Cancer Res, 2009, 15(9): 2954-61

[13] GualcoG., WeissL.M., BacchiC.E.. MUM1/IRF4: A review. Appl Immunohistochem Mol Morphol, 2010, 18(4): 301-310

[14] BiswasP.S., BhagatG., PernisA.B.. IRF-4 and its regulators: evolving insights into the pathogenesis of inflammatory arthritis?. Immunol Rev, 2010, 233(1): 79-96

[15] FanzoJ.C., YangW., JangS.Y., et al.. Loss of IRF-4-binding protein leads to the spontaneous development of systemic autoimmunity. J Clin Invest, 2006, 116(3): 703-714

[16] XiaoS., JinH., KornT., et al.. Retinoic acid increases Foxp3+ regulatory T cells and inhibits development of Th17 cells by enhancing TGF-beta-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression. J Immunol, 2008, 181(4): 2277-2284

[17] BiswasP.S., GuptaS., ChangE., et al.. Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice. J Clin Invest, 2010, 120(9): 3280-3295

[18] NurievaR.I., DongC.. Keeping autoimmunity in check: How to control a Th17 cell controller. Immunity, 2008, 29(6): 841-843